학술논문
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study.
Document Type
Article
Author
Albshesh, Ahmad; Bannon, Lian; Sharar Fischler, Tali; Truyens, Marie; Vavricka, Stephan R.; Tepes, Katja; Pugliese, Daniela; Savarino, Edoardo V.; Zittan, Eran; Drobne, David; Roblin, Xavier; Bar-Gil Shitrit, Ariella; Armuzzi, Alessandro; Lobaton, Triana; Maharshak, Nitsan; Yanai, Henit; Ben-Horin, Shomron; Kopylov, Uri
Source
Subject
*CROHN'S disease
*VEDOLIZUMAB
*DISEASE remission
*COHORT analysis
*BIOTHERAPY
*
*
*
*
Language
ISSN
2077-0383
Abstract
Background: The effectiveness of anti-TNF or ustekinumab (UST) as a second-line biologic after vedolizumab (VDZ) failure has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, We aim to investigate the effectiveness of anti-TNF and UST as second-line therapy in patients with Crohn's disease (CD) who failed VDZ as a first-line treatment. The primary outcome was clinical response at week 16–22. Secondary outcomes included the rates of clinical remission, steroid-free clinical remission, CRP normalization, and adverse events. Results: Fifty-nine patients who failed on VDZ as a first-line treatment for CD were included; 52.8% patients received anti-TNF and 47.2% UST as a second-line therapy. In initial period (Week 16–22), the clinical response and remission rate was similar between both groups: 61.2% vs. 68%, p = 0.8 and 48.3% vs. 56%, p = 0.8 on anti-TNF and UST therapy, respectively. Furthermore, in the maintenance period the rate was similar: 75% vs. 82.3%, p = 0.8 and 62.5% vs. 70.5%, p = 0.8, respectively. Of the patients, 12 out of the 59 stopped the therapy, without a significant difference between the two groups (p = 0.6). Conclusion: Second-line biological therapy after VDZ failure therapy was effective in >60% of the patients with CD. No differences in effectiveness were detected between the use of anti-TNF and UST as a second line. [ABSTRACT FROM AUTHOR]